SEARCH

SEARCH BY CITATION

References

  • 1
    Ortho-McNeil Medical Affairs Division. Topamax product information. Registered with Therapeutics Goods Administration 2002. Ortho-McNeil, Raritan, NJ, 2002.
  • 2
    Shank RP, Gardocki JF, Vaught JL et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 45060.
  • 3
    Sachdeo RC, Glauser TA, Ritter F et al. A double-blind, randomized trial of topiramate in Lennox−Gastaut syndrome. Neurology 1999; 52: 18827.
  • 4
    Biton V, Montouris GD, Ritter F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 13307.
  • 5
    Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52: 133844.
  • 6
    Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41(Suppl. 1): S6671.
  • 7
    Somerville ER. Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials? Neurology 2002; 59: 7983.
  • 8
    Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 116974.
  • 9
    Elferink JA, Van Zwieten-Boot BJ. New antiepileptic drugs: analysis based on number needed to treat show differences between drugs studied. BMJ 1997; 314: 603.
  • 10
    Ritter F, Glauser TA, Elterman RD, Wyllie E. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41 (Suppl. 1): S825.
  • 11
    Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox−Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000; 41 (Suppl. 1): S8690.
  • 12
    Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000; 41: 33841.
  • 13
    Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 2003; 107: 16575.
  • 14
    Gilliam FG, Veloso F, Bomhof MA et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003; 60: 196202.
  • 15
    Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002; 11: 40610.
  • 16
    Coppola G, Capovilla G, Montagnini A et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002; 49: 458.
  • 17
    Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, Ruiz del Portal L. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 5904.
  • 18
    Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in treatment of infantile spasms. Epilepsia 1998; 39: 13248.
  • 19
    Aldenkamp AP, Baker G, Mulder OG et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 116778.
  • 20
    Martin R, Kuzniecky R, Ho S et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999; 52: 3217.
  • 21
    Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J. Neurol. Neurosurg. Psychiatry 2000; 69: 63641.
  • 22
    Lee S, Sziklas V, Andermann F et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003; 44: 33947.
  • 23
    Ojemann LM, Ojemann GA, Dodrill CB, Crawford CA, Holmes MD, Dudley DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav. 2001; 2: 57984.
  • 24
    Takeoka M, Holmes GL, Thiele E et al. Topiramate and metabolic acidosis in paediatric epilepsy. Epilepsia 2001; 42: 38792.
  • 25
    Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002; 43: 7447.
  • 26
    Riviello JJ, Wheless J, Wu SC, Schwabe S. Body weight (BW) changes during topiramate (TPM) therapy in children with epilepsy. Epilepsia 1999; 40 (Suppl. 7): 127.
  • 27
    Clark P, Glauser TA, Hamant E, McGee K, Khoury P. Topiramate's effect on height and weight in children with partial-onset seizures. Epilepsia 1999; 40 (Suppl. 7): 115.
  • 28
    Reith D, Burke C, Appleton DB, Wallace G, Pelekanos J. Tolerability of topiramate in children and adolescents. J. Paediatr. Child Health 39: 2003; 41619.
  • 29
    Dooley JM, Camfield PR, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset − a cautionary note. Can. J. Neurol. Sci. 1999; 26: 2713.
  • 30
    Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure 2000; 9: 13741.
  • 31
    Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41 (Suppl. 1): S615.
  • 32
    Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia 1999; 40: 78891.